Parabilis Medicines, Inc. (PBLS) Stock Forecast
PBLS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $41.75 average of analyst targets
- Upside to target
- +83.5% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.45
- 52-week range
- $22.75 – $41.73
PBLS analyst ratings
5 analystsNumber of analysts at each rating.
PBLS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PBLS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.45 | −$0.25 | — | — | 3 |
| Current fiscal year (2026) | −$2.58 | −$3.09 | −$1.63 | — | — | 3 |
| Next fiscal year (2027) | −$2.19 | −$3.37 | −$1.19 | −$2.58 | +15.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PBLS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $500,000 | $0 | $1.0M | — | 2 |
| Current fiscal year (2026) | $1.0M | $0 | $3.1M | — | 3 |
| Next fiscal year (2027) | $3.3M | $0 | $10.0M | +222.6% | 3 |
PBLS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PBLS revenue: reported and forecast
PBLS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.37 | −$0.37 | −$0.38 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | −$1.66 | −$1.66 | −$2.58 | — | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$1.90 | −$1.90 | −$2.19 | — | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PBLS earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; PBLS beat in 0 of 1.
What analysts expect from PBLS
5 analysts cover Parabilis Medicines; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $41.75, 83.5% above the latest close of $22.75. Analysts expect earnings of −$2.58 per share for 2026. For 2027 the average estimate is −$2.19 per share on revenue of $3.3 million. Parabilis Medicines beat the EPS estimate in 0 of the last 1 quarters.
Related: PBLS income statement, PBLS key metrics, PBLS chart. See the PBLS stock overview for the latest quote and news.
PBLS forecast FAQ
What is Parabilis Medicines's price target?
The average analyst price target for Parabilis Medicines is $41.75, 83.5% above the latest close of $22.75.
Is Parabilis Medicines a buy, hold or sell?
Of 5 analysts covering Parabilis Medicines, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Parabilis Medicines's EPS forecast?
Analysts forecast −$2.58 per share for 2026 (range −$3.09 to −$1.63); for 2027 the estimate is −$2.19.
What is Parabilis Medicines's revenue forecast?
The average revenue estimate for 2026 is $1.0 million; for 2027 it is $3.3 million.
When does Parabilis Medicines report earnings?
Parabilis Medicines is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.45.
Does Parabilis Medicines usually beat earnings estimates?
Parabilis Medicines reported EPS at or above the analyst estimate in 0 of the last 1 quarters.